Charts

Investing in the technologies of tomorrow can be a lucrative investment strategy. If investors can discern trends as they develop, they ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs. The post 3 Meme Stocks to Sell and Replace With Meme Coins appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday,

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Moonshot Innovators ETF ETF (MOON), we found that the implied analyst target price for the ETF based upon its underlying holdings is $14.94 per unit.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript March 14, 2024 Allogene Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2023 Conference […]

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

Q4 2023 Allogene Therapeutics Inc Earnings Call

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. The post ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

2024 Financial Guidance: Anticipates a decrease in cash, cash equivalents, and investments of approximately $190 million, with GAAP Operating Expenses around $280 million. On March 14, 2024, Allogene Therapeutics Inc (NASDAQ:ALLO) released its 8-K filing, detailing the company's financial results for the fourth quarter and the full year of 2023. Allogene, a clinical-stage immuno-oncology company, is at the forefront of developing allogeneic T cell therapies for cancer treatment, with a focus on its AlloCAR T products.

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 8.51% and 54.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:02 PM. Here's what investors need ...

Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL): Start-Up Activities Underway; Enrollment to Begin Mid-2024Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Data Projected YE 2024ALLO-329 in Autoimmune Disease (AID): Differentiated Next-Generation CD19 Dagger® Program Designed for AID will Focus on Eliminating Lymphodepletion and Meeting Demand; Phase 1 Clinical Trials in Early 2025

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. • ...

Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors ...

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

The partnership is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.

Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, and Arbor Biotechnologies,

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ETSOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the mark

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $295.53 per unit.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PT/9:10 a.m. ET. Any available webcasts will be posted to the Company's website at www.allogene

No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business OperationsCompany Targeting On or Before March 14, 2024 to File Amended Financial Statements and Report Fourth Quarter and Full Year 2023 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Moonshot Innovators ETF ETF (MOON), we found that the implied analyst target price for the ETF based upon its underlying holdings is $15.47 per unit.

Investors considering a purchase of Allogene Therapeutics Inc (ALLO) shares, but cautious about paying the going market price of $3.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May put at the $2.50 strike, which has a bid at the time of this writing of 25 cents..

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology ConferenceThursday, January 18, 202412:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWednesd

Allogene Therapeutics Inc(NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND ...

Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released ...

Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Allogene and ALLO stock aren't cheering a cash burn reduction strategy, with the stock sinking over 15% on the news. The post Allogene Layoffs 2024: What to Know About the Latest ALLO Job Cuts appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

In trading on Friday, biotechnology shares were relative laggards, down on the day by about 1.1%. Helping drag down the group were shares of Voyager Therapeutics, down about 18.5% and shares of Allogene Therapeutics off about 16.2% on the day.

Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. Shares of Franklin Covey ...

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock increased by 113.1% to $1.3 during Thursday's after-market session. The market value ...

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Kensho New Economies Composite ETF (KOMP), we found that the implied analyst target price for the ETF based upon its underlying holdings is $52.17 per unit.

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial ...

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Is the 'smart money' on the money shorting these low-float penny stocks, or is there the opportunity for a short squeeze? Let's find out. The post 7 Penny Stocks With Low Floats and High Short Interest appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The #1 AI Investment Might Be This Company You’ve Never Heard Of The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. Seres Therapeutics, Inc. (NASDAQ: MCRB) climbed 45.9% to ...

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in ...

Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here's what investors ...

Investors eyeing a purchase of Allogene Therapeutics Inc (ALLO) shares, but cautious about paying the going market price of $2.58/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2024 put at the $2.50 strike, which has a bid at the time of this writing of 35 cents..

Wall Street price targets suggest this stock can rocket more than 400% higher.

U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in ...

Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $289.26 per unit.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Wondering what are the most shorted stocks this year? Here are the top five companies investors are betting against. The post Short Squeeze Alert: The 5 Most Shorted Stocks Right Now appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Did Elon Musk Just Trigger a New Netscape Moment? The $1 Investment You MUST Take Advantage of Right Now The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Thursday,Allogene Therapeutics Inc(NASDAQ: ALLO) presented the updated data from the Phase 1 ALPHA/ALPHA2 trials of ...

Allogene Therapeutics, Inc. (NASDAQ: ALLO) shares are trading lower after the company announced its CFO Eric Schmidt will step down from ...

Gainers Blue Water Biotech (NASDAQ:BWV) shares increased by 61.4% to $1.27 during Wednesday's regular session. Trading volume for Blue ...

Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing ...

Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The best stocks to short are companies whose businesses aren’t faring well and have a higher-than-average short interest. The post The 3 Best Stocks to Short in May 2023 appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period. The post 7 Short-Interest Stocks to Target for Explosive Gains appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

Sen. Dianne Feinstein of California, one of the wealthiest members of Congress, continues to draw ire for her questionable stock trading ...

Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 89.3% to $7.44. Actelis Networks, Inc. (NASDAQ: ASNS) gained 68.7% to ...

U.S. stocks traded lower, with the Dow Jones falling around 400 points on Thursday. Here are some big stocks recording gains in ...

Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Allogene Therapeutics (NASDAQ:ALLO) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:02 PM. Here's what investors need ...

U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although moving against the grain presents its own distinct set of risks, these short-squeeze stocks may profit the contrarian. The post 7 Short-Squeeze Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in ...